Patents by Inventor Seppo Yla-Herttuala

Seppo Yla-Herttuala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080280363
    Abstract: A viral G protein-pseudotyped baculovirus, in which the G protein is truncated and comprises the ectodomain, transmembrane domain and cytoplasmic tail domain. Such a baculovirus can be used for transduction of cells and for gene therapy.
    Type: Application
    Filed: November 3, 2005
    Publication date: November 13, 2008
    Inventors: Kari Juhani Airenne, Seppo Yla-Herttuala, Minna U Kaikkonen, Jani K. Raty
  • Publication number: 20080261234
    Abstract: A peptide having affinity for oxidised low density lipoprotein, in cyclised or multimeric form is useful in an enzyme immunosolvent assay, to detect oxLDL which is a marker of coronary heart disease.
    Type: Application
    Filed: May 4, 2007
    Publication date: October 23, 2008
    Inventors: Outi Narvanen, Seppo Yla-Herttuala
  • Patent number: 7393677
    Abstract: The present invention pertains to an avidin-pseudotyped virus, and especially baculovirus, useful for delivery of foreign genes etc. The present invention also pertains to vectors comprising respective cassettes for pseudotyping, mammalian gene expression and insect gene expression in baculovirus.
    Type: Grant
    Filed: July 6, 2006
    Date of Patent: July 1, 2008
    Assignee: Ark Therapeutics, Ltd.
    Inventors: Kari Juhani Airenne, Anssi Mahonen, Seppo Yla-Herttuala
  • Publication number: 20080147045
    Abstract: The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery.
    Type: Application
    Filed: July 24, 2007
    Publication date: June 19, 2008
    Applicants: Licentia Ltd., Ludwig Institute for Cancer Research
    Inventors: Kari Alitalo, Anne Saaristo, Marika Karkkainen, Tuomas Tammela, Sirpa Asko-Seljavaara, Seppo Yla-Herttuala, Yulong He
  • Patent number: 7320679
    Abstract: The present invention concerns vascular endothelial growth factor (VEGF) which has utility in the treatment of intimal hyperplasia, hypertension and atherosclerosis, and of conditions susceptible to treatment with agents that produce nitric oxide or prostacyclin. Instead of VEGF, an equivalent agent such as an agonist of VEGF receptors may be given, as may nucleic acid encoding such an agonist. The agent may successfully be administered via the adventitial surface of a blood vessel, e.g., using a device which defines a reservoir between the body wall and the vessel's adventitial surface, the reservoir being at least part-filled by a pharmaceutical formulation containing the agent to be delivered.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: January 22, 2008
    Assignee: Ark Therapeutics, Ltd.
    Inventors: John Francis Martin, Seppo Yla-Herttuala, Stephen George Edward Barker
  • Publication number: 20070224675
    Abstract: An expression cassette comprises targeting sites flanking a Cre fusion gene and a Cre coding sequence interrupted by an intron. This cassette can be used for the generation CreAoxP constructs and to reduce toxicity caused by the over-expression of Cre in target cells.
    Type: Application
    Filed: May 20, 2005
    Publication date: September 27, 2007
    Inventors: Kari Airenne, Anssi Mahonen, Seppo Yla-Herttuala
  • Publication number: 20070142282
    Abstract: The present invention is directed to methods and compositions for making and using chimeric polypeptides that comprise a VEGFR-2 ligand. The chimeric molecules of the present invention retain VEGFR-2 binding activity and an enhanced angiogenic activity as compared to native VEGF-A.
    Type: Application
    Filed: August 15, 2006
    Publication date: June 21, 2007
    Applicants: LUDWIG INSTITUTE FOR CANCER RESEARCH, LICENTIA LTD.
    Inventors: Kari Alitalo, Tuomas Tammela, Salla Keskitalo, Katri Pajusola, Markku Jeltsch, Seppo Yla-Herttuala, Terhi Karpanen, Ulf Eriksson, Marko Uutela
  • Patent number: 7208291
    Abstract: The present invention pertains to a novel transmembrane protein capable of binding to biotinylated molecules, the protein comprising a cytoplasmic domain, a membrane-spanning domain and an extracellular domain, wherein the extracellular domain comprises biotin-binding activity.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: April 24, 2007
    Assignee: Ark Therapeutics Limited
    Inventors: Seppo Yla-Herttuala, Markku Kulomaa, Pauliina Lehtolainen, Varpu Marjomaki, Kari Airenne
  • Publication number: 20060246091
    Abstract: The present invention pertains to an avidin-pseudotyped virus, and especially baculovirus, useful for delivery of foreign genes etc. The present invention also pertains to vectors comprising respective cassettes for pseudotyping, mammalian gene expression and insect gene expression in baculovirus.
    Type: Application
    Filed: July 6, 2006
    Publication date: November 2, 2006
    Inventors: Kari Airenne, Anssi Mahonen, Seppo Yla-Herttuala
  • Publication number: 20060093653
    Abstract: The subject invention pertains to a biodegradable matrix material which is provided in a form that can be wrapped around a body part, in combination or impregnated with an agent that can be delivered to treat a condition via the adventitial surface of a body part, the agent being in a form that can be taken up by the matrix material. These components are provided for use in the treatment of the condition, for example, by using a sealant to form a seal around the matrix material when impregnated with the agent.
    Type: Application
    Filed: October 18, 2005
    Publication date: May 4, 2006
    Inventors: John Martin, Seppo Yla-Herttuala, Stephen Edward Barker
  • Publication number: 20050256075
    Abstract: The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
    Type: Application
    Filed: February 24, 2005
    Publication date: November 17, 2005
    Inventors: Kari Alitalo, Seppo Yla-Herttuala, Mikko Hiltunen, Markku Jeltsch, Marc Achen
  • Patent number: 6958147
    Abstract: The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: October 25, 2005
    Assignees: Licentia Ltd, Seppo Yla-Herttuala, Ludwig Institute of Cancer Research
    Inventors: Kari Alitalo, Seppo Ylä-Herttuala, Mikko O. Hiltunen, Markku M. Jeltsch, Marc G. Achen
  • Publication number: 20050201983
    Abstract: Baculovirus is engineered so that the capsid displays one or more heterologous peptides or protein. Such baculovirus can be used to deliver therapeutics, and in functional genomics.
    Type: Application
    Filed: March 12, 2003
    Publication date: September 15, 2005
    Inventors: Seppo Yla-Herttuala, Kari Airenne
  • Publication number: 20050043235
    Abstract: The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement: of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery.
    Type: Application
    Filed: June 14, 2004
    Publication date: February 24, 2005
    Inventors: Kari Alitalo, Anne Saaristo, Marika Karkkainen, Tuomas Tammela, Sirpa Asko-Seljavaara, Seppo Yla-Herttuala, Yulong He
  • Publication number: 20050002981
    Abstract: The present invention relates to the use of a gene transfer product to reduce hyperplastic connective tissue growth after tissue trauma or implantation of a medical device. The present invention also relates to a medical device with improved biological properties for an at least partial contact with blood, bodily fluids and/or tissues when introduced in a mammalian body, which device comprises a core and a nucleic acid, encoding a product capable of leading to production of extracellular superoxide dismutase present in a biologically compatible medium. Said nucleic acid encodes a translation or transcription product, which is capable of inhibiting hyperplastic connective tissue growth and promoting endothelialisation in vivo at least partially on a synthetic surface of said core. The present invention also relates to a method of producing a medical device according to the invention.
    Type: Application
    Filed: October 28, 2003
    Publication date: January 6, 2005
    Inventors: Mika Lahtinen, Mikko Laukkanen, Seppo Yla-Herttuala, Olli-Pekka Leppanen
  • Publication number: 20040248796
    Abstract: The present invention provides materials and methods for VEGF-B and PDGF therapy, especially therapy directed at stem cell recruitment, proliferation, and/or differentiation.
    Type: Application
    Filed: February 4, 2004
    Publication date: December 9, 2004
    Inventors: Kari Alitalo, Ulf Eriksson, Peter Carmeliet, Xuri Li, Desire Collen, Seppo Yla-Herttuala, Petri Salven, Iiro Rajantie
  • Publication number: 20040208905
    Abstract: A baculovirus is used for gene therapy of a condition that can be mediated via the spinal cord or CNS.
    Type: Application
    Filed: April 29, 2004
    Publication date: October 21, 2004
    Inventors: Seppo Yla-Herttuala, Kari Juhani Airenne, Pauliina Lehtolainen
  • Publication number: 20040185059
    Abstract: The present invention pertains to a novel transmembrane protein capable of binding to biotinylated molecules, the protein comprising a cytoplasmic domain, a membrane-spanning domain and an extracellular domain, wherein the extracellular domain comprises biotin-binding activity.
    Type: Application
    Filed: July 11, 2003
    Publication date: September 23, 2004
    Inventors: Seppo Yla-Herttuala, Markku Kulomaa, Pauliina Lehtolainen, Varpu Marjomaki, Kari Airenne
  • Publication number: 20040146487
    Abstract: The present invention pertains to an avidin-pseudotyped virus, and especially baculovirus, useful for delivery of foreign genes etc. The present invention also pertains to vectors comprising respective cassettes for pseudotyping, mammalian gene expression and insect gene expression in baculovirus.
    Type: Application
    Filed: March 15, 2004
    Publication date: July 29, 2004
    Inventors: Kari Juhani Airenne, Anssi Mahonen, Seppo Yla-Herttuala
  • Publication number: 20040091934
    Abstract: A peptide having affinity for oxidised low density lipoprotein, in cyclised or multimeric form is useful in an enzyme immunosolvent assay, to detect oxLDL which is a marker of coronary heart disease.
    Type: Application
    Filed: July 2, 2003
    Publication date: May 13, 2004
    Inventors: Outi Narvanen, Seppo Yla-Herttuala